BridgeBio Pharma Inc [BBIO] stock prices are up 13.12% to $27.85 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The BBIO shares have gain 10.04% over the last week, with a monthly amount glided 6.38%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, BMO Capital Markets started tracking the stock with Market Perform rating on January 31, 2024, and set its price target to $37. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $58 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating. Citigroup initiated its recommendation with a Buy and recommended $42 as its price target on November 07, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 24, 2023, and assigned it a price target of $50. In a note dated July 18, 2023, Jefferies downgraded an Hold rating on this stock and boosted its target price from $24 to $33.
The stock price of BridgeBio Pharma Inc [BBIO] has been fluctuating between $21.62 and $44.32 over the past year. Currently, Wall Street analysts expect the stock to reach $43.75 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $27.85 at the most recent close of the market. An investor can expect a potential return of 57.09% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
The BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 219.12M for trailing twelve months, representing a surge of 32.11%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.3%, Pretax Profit Margin comes in at -2.09%, and Net Profit Margin reading is -2.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is 0.39 and Total Capital is -0.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.38 points at the first support level, and at 24.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.79, and for the 2nd resistance point, it is at 29.73.
Ratios To Look Out For
It’s worth pointing out that BridgeBio Pharma Inc [NASDAQ:BBIO]’s Current Ratio is 4.59. On the other hand, the Quick Ratio is 4.59, and the Cash Ratio is 4.07. Considering the valuation of this stock, the price to sales ratio is 23.90.
Transactions by insiders
Recent insider trading involved Kumar Neil, Chief Executive Officer, that happened on Aug 19 ’24 when 27389.0 shares were sold. Secretary, Treasurer & CFO, STEPHENSON BRIAN C completed a deal on Aug 19 ’24 to sell 4155.0 shares. Meanwhile, Officer BRIAN STEPHENSON bought 4155.0 shares on Aug 19 ’24.
